H.C. Wainwright Remains a Buy on Inventiva (IVA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Inventiva (IVA – Research Report), with a price target...
Source: businessinsider.com
📰 Ed Arce News
Page 3 - Ed Arce News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ed Arce. Real-time updates on events, politics, business and more.
Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday - Camtek (NASDAQ:CAMT), Casey's General Stores (NASDAQ:CASY)
B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02 in pre-market trading.
Source: benzinga.com
Positive Report for Intercept Pharma (ICPT) from H.C. Wainwright
Intercept Pharma (ICPT – Research Report) received a Buy rating and a $19.00 price target from H.C. Wainwright analyst Ed Arce today. The ...
New York United States Ed Arce Marke Pruzanski Canaccord Genuity Edward Nash Intercept Pharmaceuticals Inc
Source: businessinsider.com
Approval Sought in Japan for New SARS-CoV-2 Vaccine
Approval Sought in Japan for New SARS-CoV-2 Vaccine
Ed Arce Seika Pharma Arcturus Therapeutics Holdings Inc Hc Wainwright Co Axcelead Inc Therapeutics Holdings
Source: investorideas.com
Why Shares of CymaBay Therapeutics Are Soaring Friday
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
Source: fool.com
H.C. Wainwright Reaffirms Their Buy Rating on Inventiva (IVA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Inventiva (IVA – Research Report), with a price target...
Source: businessinsider.com
Key Catalyst for US Biopharma Stock on Track for Q4/23
Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: investorideas.com
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2023 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded.
Source: insidermonkey.com
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q1 2023 Earnings Call Transcript
Operator: Hello, welcome to the AcelRx First Quarter 2023 Financial Results Conference Call.
Source: insidermonkey.com